$8.86
0.56% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
CA31447P1009
Symbol
FENC

Fennec Pharmaceuticals Inc. Stock price

$8.86
+0.54 6.49% 1M
+2.09 30.87% 6M
+2.54 40.19% YTD
+3.25 57.93% 1Y
+1.47 19.89% 3Y
+3.61 68.76% 5Y
+6.67 304.14% 10Y
-46.98 84.13% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.05 0.56%
ISIN
CA31447P1009
Symbol
FENC
Industry

Key metrics

Basic
Market capitalization
$246.6m
Enterprise Value
$246.1m
Net debt
positive
Cash
$18.7m
Shares outstanding
27.7m
Valuation (TTM | estimate)
P/E
negative | 94.0
P/S
7.4 | 5.1
EV/Sales
7.4 | 5.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-13.1%
Return on Equity
7.4%
ROCE
-26.5%
ROIC
-
Debt/Equity
-2.4
Financials (TTM | estimate)
Revenue
$33.3m | $48.0m
EBITDA
- | $17.6m
EBIT
$-9.7m | $2.7m
Net Income
$-12.0m | $2.6m
Free Cash Flow
$-12.0m
Growth (TTM | estimate)
Revenue
-31.9% | 1.0%
EBITDA
- | -
EBIT
-258.0% | 6.6%
Net Income
-515.2% | 693.2%
Free Cash Flow
-151.4%
Margin (TTM | estimate)
Gross
89.9%
EBITDA
- | 36.8%
EBIT
-29.1%
Net
-36.2% | 5.5%
Free Cash Flow
-36.1%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
6.6%
Employees
32
Rev per Employee
$1.5m
Show more

Is Fennec Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy
91%
Hold
9%

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
33 33
32% 32%
100%
- Direct Costs 3.37 3.37
55% 55%
10%
30 30
36% 36%
90%
- Selling and Administrative Expenses 40 40
4% 4%
119%
- Research and Development Expense 0.35 0.35
75% 75%
1%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.67 -9.67
258% 258%
-29%
Net Profit -12 -12
515% 515%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about Fennec Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fennec Pharmaceuticals Inc. Stock News

Neutral
Seeking Alpha
16 days ago
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Jeffrey S. Hackman - CEO & Director Robert C.
Neutral
GlobeNewsWire
21 days ago
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support Services for PEDMARK ® ~ ~ Successful Initial Uptake of PEDMARQSI® in the United Kingdom and Germany w...
Neutral
GlobeNewsWire
24 days ago
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day...
More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office Canada
CEO Jeffrey Hackman
Employees 32
Founded 1996
Website fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today